Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment.
Meijer
J M
JM
Pijpe
J
J
Vissink
A
A
Kallenberg
C G M
CG
Bootsma
H
H
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D019233:Retreatment; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab